(E)-3-(4-Methylsulfonyl)phenyl-1-morpholin-4-yl-2-phenylbut-2-en-1-one | 194736-68-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-3-(4-Methylsulfonyl)phenyl-1-morpholin-4-yl-2-phenylbut-2-en-1-one
• 英文别名: (E)-3-(4-methylsulfonylphenyl)-1-morpholin-4-yl-2-phenylbut-2-en-1-one
• CAS: 194736-68-0
• 化学式: C₂₁H₂₃NO₄S
• 分子量: 385.484
• InChiKey: RHVCDEKTDJRIEN-CAPFRKAQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• DIPHENYL STILBENES AS PRODRUGS TO COX-2 INHIBITORS
  申请人：Merck Frosst Canada & Co.

  公开号：EP0882015B1

  公开（公告）日：2000-12-27
• COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN
  申请人：Algos Pharmaceutical Corporation

  公开号：EP1146905A1

  公开（公告）日：2001-10-24
• US5733909A
  申请人：——

  公开号：US5733909A

  公开（公告）日：1998-03-31
• [EN] DIPHENYL STILBENES AS PRODRUGS TO COX-2 INHIBITORS<br/>[FR] STILBENES DE DIPHENYLE UTILISES EN TANT QUE PROMEDICAMENTS D'INHIBITEURS DE COX-2
  申请人：MERCK FROSST CANADA INC.

  公开号：WO1997028120A1

  公开（公告）日：1997-08-07

  (EN) The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).(FR) La présente invention concerne le composé nouveau de formule (I), utile dans le traitement de maladies à médiation par la cyclooxygénase-2. L'invention concerne aussi certaines compositions pharmaceutiques comprenant des composés de formule (I) et destinées au traitement de ces maladies.
• [EN] COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN<br/>[FR] UTILISATION D'UNE COMBINAISON D'INHIBITEURS DE COX-2 ET DE SUBSTANCES BLOQUANT LES RECEPTEURS DE NMDA POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ALGOS PHARM CORP

  公开号：WO2000029023A1

  公开（公告）日：2000-05-25

  A method of alleviating a pain state not associated with a cough condition is provided which comprises administering to a mammal exhibiting a pain state not associated with a cough condition a cyclooxygenase-2 inhibitor with a nontoxic NMDA receptor antagonist and/or a nontoxic substance that blocks at least one major intracellular consequence of NMDA receptor activation.